The short answer
An experimental medicine produced substantial weight loss, but safety findings stopped its development.
What was tested?
NN1177 targeted both glucagon and GLP-1 receptors. Three early studies included a 12-week trial randomizing 99 adults with overweight or obesity across several doses and placebo.
Only 68 completed that trial. Some dose groups enrolled replacement participants after withdrawals.
12-week trial; 99 randomized across several doses and placebo
Weight result
One small dose group exceeded placebo
Safety findings
Heart rate, glucose tolerance and blood-test changes
Development
Ended after safety concerns
Original visual based on the study.
| Group or measure | Result |
|---|---|
| Weight result | One small dose group exceeded placebo |
| Safety findings | Heart rate, glucose tolerance and blood-test changes |
| Development | Ended after safety concerns |
What did researchers find?
At one dose, estimated weight loss exceeded placebo by 12.6 percentage points. This was a small dose group, not the average for all 99 participants.
However, researchers also observed faster heart rates, changes in heart-rhythm measurements, worsened glucose tolerance and abnormal blood-test results. Digestive side effects and other problems led to withdrawals.
The investigators reported that the safety concerns ended clinical development.
What does this teach us?
A large weight-loss headline does not establish a medicine’s overall value. Early trials must assess what happens beyond the scale.
These findings concern this compound, not every medicine targeting similar receptors.
Novo Nordisk funded medical writing; several authors worked for the developer.
A later correction restored a missing baseline table without changing the findings.
Sources
Friedrichsen and colleagues, Molecular Metabolism, 2023 · Correction, 2024